UK Researcher Accepts KPA Psychologist of the Year Honor
Markesbery Symposium Focuses on Healthy Brain Aging, Care for Caregivers
Pediatric Surgery Chief leads record-setting benefit for March of Dimes
By Josh Shepherd
University of Kentucky Department of Surgery
The 2016 Greater Bluegrass Signature Chefs Auction set a new fundraising record for this event on Friday night, Nov. 4, at the Marriott Griffin Gate Resort, according to Dr. Joe Iocono, division chief of UK Pediatric Surgery, who served as the event chair this year.
Gill Heart Institute Cardiovascular Research Day Presents Scientific Achievement in Heart Health
SCoBIRC Graduate Student Wins Award
LEXINGTON, Ky. (Nov. 3, 2016) —The second annual Thomas V. Getchell, Ph.D., Memorial Award for excellence in grant writing was presented to Jenna Gollihue, a graduate student in the University of Kentucky Spinal Cord and Brain Injury Research Center, on Nov. 2. The award honors the memory of Getchell, a former professor of physiology in the UK Department of Physiology who encouraged researchers to improve grant writing skills to acquire research funding. The award supports a travel stipend for a student participating in the annual Grant Writing Workshop.
UK Researcher Highlighted by National Cancer Institute
National leader in surgical resident training to deliver annual Schwartz Memorial lecture
A leading researcher and analyst of surgical resident training will deliver the annual Richard Schwartz Memorial lecture at the W.T. Young Library Auditorium on Thursday evening, November 10.
Gary Dunnington, the Jay L. Grossfeld Professor and Chair of Surgery at Indiana University School of Medicine, has been an author and contributor to numerous publications regarding operative performance assessments of surgeons during general residency and fellowship training.
Proposed Clinical Trial Could Change the Game for Deadly Type of Breast Cancer
University of Kentucky Markey Cancer Center Oncologist Dr. Edward Romond spent his career at UK treating and studying breast cancer, even leading major Phase 3 clinical trials on the breast cancer drug trastuzumab in the early 2000s. Commonly known as Herceptin, this drug became a standard of care for patients with HER2-positive breast cancer.
Though he retired from practice last year, Romond continues to work part-time with the research team at Markey, this time pushing toward a cure for a different, more deadly, type of breast cancer.